Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY-NC-NDFuture oncology (London, England)

A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.

  • Helena A Yu1
  • Yasushi Goto2
  • Pasi A Jänne3,4,5
5 affiliations
  1. 1aDepartment of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, United States.
  2. 2bNational Cancer Center Hospital, Tokyo, Japan.
  3. 3cDepartment of Medical Oncology, Dana-Farber Cancer Institute Department of Medical Oncology, Massachusetts, Boston, United States.
  4. 4dHarvard Medical School, Massachusetts, Boston, United States.
  5. 5eDepartment of Medicine, Brigham and Women's Hospital, Massachusetts, Boston, United States.
Read full textPDFDOICite

Related

  1. ERBB2 Exon 20 Mutation-Guided Trastuzumab Deruxtecan Therapy in Metastatic Lung Adenocarcinoma with Low HER2 Expression: A Case Report.
    Zhao-Feng Gao, Xu Wen, Jia-Qi Yu +5
    OncoTargets and therapyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Comparative Safety Profiles of Sacituzumab Govitecan and Datopotamab Deruxtecan: A Real-World Pharmacovigilance Study
    Ziya Kalkan, Murat Bardakci, Tugba Tezer Kalkan +1
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report
    Myrtille Thomas, Mojgan Devouassoux-Shisheboran, Jonathan Lopez +5
    Gynecologic Oncology ReportsPeer-reviewedCC BYFull textGeneral biologyEpidemiology & public healthHAL
  4. Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1+
    Angelika Wolfrum, Julia Ladurner, Burghard Abendstein
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  5. From Lethargy to Recovery: Central Diabetes Insipidus from Pituitary Metastasis in Recurrent HER2-Positive Breast Cancer Treated with Fam-Trastuzumab Deruxtecan-Nxki
    Sushrut Ingawale, Yasheen Gao, Kirit Dhanjal +3
    Journal of Brown hospital medicinePeer-reviewedCC BY-NCFull textEndocrinology & metabolismEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{yu2026study,
  title = {{A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.}},
  author = {Helena A Yu and Yasushi Goto and Pasi A Jänne},
  journal = {Future oncology (London, England)},
  year = {2026},
  month = sep,
  doi = {10.1080/14796694.2026.2691681},
  url = {https://europepmc.org/article/MED/42860885},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.
AU  - Helena A Yu
AU  - Yasushi Goto
AU  - Pasi A Jänne
PY  - 2026
DA  - 2026/09/01
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2691681
UR  - https://europepmc.org/article/MED/42860885
SN  - 1479-6694
SN  - 1744-8301
ER  -